Cambrian Biopharma

Amplifier Therapeutics is a biopharmaceutical company dedicated to developing novel therapies targeting AMP-activated protein kinase (AMPK), a key regulator of cellular energy balance. The company's focus is on treating age-related disorders, including metabolic conditions, cardiovascular diseases, kidney diseases, and certain types of cancer, by activating AMPK to restore normal cellular function.

Vita Therapeutics is a cell engineering company focused on developing innovative treatments for debilitating neuromuscular diseases and cancers. The company employs induced pluripotent stem cell (iPSC) technology to create specific cell types that can replace defective cells in patients. By targeting the underlying causes of these diseases, Vita Therapeutics aims to provide truly curative cellular medicines, offering new hope for individuals affected by these conditions.

Oviva Therapeutics is focused on enhancing women's health as they age by developing therapeutics aimed at improving ovarian function. The company engages in biomedical research and clinical development to create effective treatments that address female physiology, particularly concerning ovarian aging. In addition to its research initiatives, Oviva Therapeutics advocates for better awareness and understanding of women's health issues. By collaborating with scientists and clinicians, the company aims to drive meaningful advancements in the field, ultimately improving the overall experience of aging for women.

Vita Therapeutics is a cell engineering company focused on developing innovative treatments for debilitating neuromuscular diseases and cancers. The company employs induced pluripotent stem cell (iPSC) technology to create specific cell types that can replace defective cells in patients. By targeting the underlying causes of these diseases, Vita Therapeutics aims to provide truly curative cellular medicines, offering new hope for individuals affected by these conditions.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Samsara Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapies for age-related diseases and unmet medical needs. Founded in 2018 and headquartered in Hamburg, Germany, with additional operations in Oxford, Paris, Graz, and San Diego, the company utilizes a unique screening platform centered on geroprotectors to create caloric restriction mimetics (CRM) that target the core mechanisms of aging, such as proteostasis, autophagy, and energy metabolism. Samsara's research and development activities include the identification, chemical optimization, and in vivo validation of compounds that aim to extend healthy lifespan and address rare genetic and neurodegenerative disorders.